Digestive Disease Center and Research Institute, Department of Internal Medicine, SoonChunHyang University School of Medicine, Bucheon, Korea.
J Gastroenterol Hepatol. 2019 Jul;34(7):1208-1213. doi: 10.1111/jgh.14602. Epub 2019 Feb 18.
Fully covered self-expandable metal stent (FCSEMS) are preferred for distal malignant biliary stricture (MBS). However, stent migration is a major adverse event of FCSEMS, especially for far distal MBS. We evaluated the usefulness of newly modified FCSEMS (M-FCSEMS) having 12 mm in diameter and anti-migration feature to minimize stent migration compared with the conventional FCSEMS (C-FCSEMS).
Total 102 patients were enrolled between January 2015 and September 2017 in this prospective comparative study; 50 were allocated to the M-FCSEMS group and 52 to the C-FCSEMS group. The primary outcome was stent migration, and the secondary outcomes were other adverse events, stent occlusion rate, and stent patency during the follow-up period.
The baseline characteristics of the two groups did not significantly differ. Endoscopic stent placement was technically successful in all patients. Stent migration occurred in 8.0% (4/50) of the patients in the M-FCSEMS group and 23.1% (12/52) of those in the C-FCSEMS group (P = 0.036). The other adverse events, including stent-related pancreatitis and cholecystitis did not significantly differ between the two groups (P = 0.415). Stent occlusion occurred in 23.9% (11/46) of the patients in the M-FCSEMS group and 37.5% (15/40) in the C-FCSEMS group (P = 0.171). Stent patency was significantly longer in the M-FCSEMS group than in the C-FCSEMS group (228 vs 157 days, P = 0.048).
Modified FCSEMS with 12-mm diameter and anti-migration feature significantly decreased the risk of stent migration and had longer patency compared with C-FCSEMS in patients with periampullary MBS.
全覆膜自膨式金属支架(FCSEMS)是治疗远端恶性胆道狭窄(MBS)的首选方法。然而,支架迁移是 FCSEMS 的主要不良事件,尤其是对于远端 MBS。我们评估了新改良的 FCSEMS(M-FCSEMS)的有效性,其具有 12mm 直径和抗迁移特性,可最大程度减少支架迁移的风险,与传统 FCSEMS(C-FCSEMS)相比。
本前瞻性对照研究共纳入 2015 年 1 月至 2017 年 9 月期间的 102 例患者;其中 50 例患者被分配到 M-FCSEMS 组,52 例患者被分配到 C-FCSEMS 组。主要结局是支架迁移,次要结局是其他不良事件、支架闭塞率和随访期间的支架通畅率。
两组患者的基线特征无显著差异。所有患者的内镜下支架置入均获得技术成功。M-FCSEMS 组患者中有 8.0%(4/50)发生支架迁移,C-FCSEMS 组患者中有 23.1%(12/52)发生支架迁移(P=0.036)。两组患者的其他不良事件,包括支架相关胰腺炎和胆囊炎,差异无统计学意义(P=0.415)。M-FCSEMS 组患者中有 23.9%(11/46)发生支架闭塞,C-FCSEMS 组患者中有 37.5%(15/40)发生支架闭塞(P=0.171)。M-FCSEMS 组的支架通畅时间明显长于 C-FCSEMS 组(228 天 vs 157 天,P=0.048)。
对于胰胆管交界部 MBS 患者,改良的 12mm 直径和抗迁移特性的 FCSEMS 可显著降低支架迁移的风险,并具有比 C-FCSEMS 更长的通畅时间。